National Research Corp

National Research Corp (NRC) Stock Analysis

$20.470

+0.325 (+1.59%)At close

Loading chart…
High
20.965
Open
20.180
VWAP
20.47
Volume
68.41K
Mkt Cap
548.94M
Low
19.980
Amount
1.40M
EV/EBITDA, TTM
65.13

NRC Health, formerly National Research Corporation, provides healthcare experience improvement solutions. The Company is focused on improving the challenged healthcare ecosystem with stakeholder experience insights, market intelligence data, and software tools that enable health systems to improve patient outcomes and hospital operations. Its solutions consist of four solution categories: Patient Experience, Consumer Experience, Employee Experience, and Market Experience. The Company's portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.

nrchealth.com

AI analysis of National Research Corp (NRC)

Hold

Currently, NRC is not a strong buy due to its recent price decline and mixed financial performance. The current price is $20.15, with an RSI of 42.58 indicating it is nearing oversold territory. The forward P/E ratio is 17.21, suggesting reasonable valuation compared to its growth potential. However, the recent 5-day change is -0.89% and the 20-day change is -1.99%, indicating a downward trend. The main risk is the negative net income reported in Q2 2026, which was -$328,300, highlighting potential profitability issues. While the company has a solid long-term growth outlook, short-term volatility may warrant a hold position for now.

Valuation Metrics

The current forward P/E ratio for National Research Corp (NRC) is 17.21, compared to its 5-year average forward P/E of 26.12.

Forward P/E

Fair
5Y Average P/E
26.12
Current P/E
17.21
Overvalued
36.17
Undervalued
16.07

Forward EV/EBITDA

Strongly Overvalued
5Y Average EV/EBITDA
19.53
Current EV/EBITDA
65.13
Overvalued
33.89
Undervalued
5.16

Forward P/S

Undervalued
5Y Average P/S
5.76
Current P/S
2.93
Overvalued
8.14
Undervalued
3.39

Events Timeline

2026-08-12 (ET)

16:30:00

Resideo Appoints Shane Harrison as CFO

2026-05-19 (ET)

09:20:00

NRC Health Introduces New AI Features to Enhance Healthcare Interactions

2026-04-07 (ET)

09:20:00

NRC Health Expands Partnership with Ann & Robert H. Lurie Children's Hospital

2026-03-09 (ET)

16:40:00

NRC Health Authorizes Stock Repurchase Program Up to $60M

2026-03-04 (ET)

16:30:00

National Research Corporation TRCV Surpasses $152 Million

News

NRC FAQ — answered by Alphio AI

NRC Health, formerly National Research Corporation, provides healthcare experience improvement solutions. The Company is focused on improving the challenged healthcare ecosystem with stakeholder experience insights, market intelligence data, and software tools that enable health systems to improve patient outcomes and hospital operations. Its solutions consist of four solution categories: Patient Experience, Consumer Experience, Employee Experience, and Market Experience. The Company's portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. It operates in the Industrials sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

Currently, NRC is not a strong buy due to its recent price decline and mixed financial performance. The current price is $20.15, with an RSI of 42.58 indicating it is nearing oversold territory. The forward P/E ratio is 17.21, suggesting reasonable valuation compared to its growth potential. However, the recent 5-day change is -0.89% and the 20-day change is -1.99%, indicating a downward trend. The main risk is the negative net income reported in Q2 2026, which was -$328,300, highlighting potential profitability issues. While the company has a solid long-term growth outlook, short-term volatility may warrant a hold position for now.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading